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Introduction
Th   e liver is amongst the largest lymphoid organs and acts 
not only as a site of tolerance but also as a primary line of 
defense in mucosal immunobiology [1]. Additionally, 
there is a critical interplay within the liver between the 
primary role of protection against infections and the 
seemingly contrary role of maintaining tolerance. Th  is 
interplay becomes particularly important in the case of 
chronic viral hepatitis, in which the immune response 
often becomes relatively ineﬀ  ective. In contrast, there is 
increasing evidence for the critical role of the liver in 
modulating the immune response in autoimmune and 
chronic inﬂ  ammatory diseases [2-4]. Th   is is represented 
by the central role of the liver microcirculation in 
main  tain  ing immune tolerance while initiating an 
adequate response to infectious agents; examples of the 
implica  tions of these phenomena are illustrated by the 
putative role of molecular mimicry in the onset of 
autoimmune diseases [1].
A wide spectrum of rheumatic diseases can aﬀ  ect the 
liver with various degrees of involvement and histopatho-
logical features; these features are not speciﬁ  c to such 
comorbidities and are based on clinical features that are 
common to other chronic liver diseases [5]. In contrast, 
the primary immune diseases of the liver are autoimmune 
hepatitis (AIH) [6], primary biliary cirrhosis (PBC) [7], 
and primary sclerosing cholangitis (PSC) [8]. Th  ese  three 
major autoimmune liver diseases have prevalence rates of 
100 cases per million (AIH), 400 cases per million (PBC), 
and 150 cases per million (PSC) [9]. PBC and PSC are 
primarily biliary/cholestatic diseases with involvement of 
liver parenchyma only as a secondary manifestation; as 
such, their liver biochemistry proﬁ  le reﬂ  ects cholestasis. 
AIH results from hepatocyte damage with a typical 
hepatitis pattern of liver tests.
Liver histology for the rheumatologist
Liver involvement in patients with rheumatic disease 
manifests typical, although not speciﬁ  c, histopathological 
features that may pose a dilemma with primary liver 
conditions [10]. Th  e typical liver histology of AIH [11] 
includes portal–parenchymal interface hepatitis with 
abundant lymphocyte and plasma cell inﬁ  ltrates  that 
cross the limiting plate and invade the liver parenchyma 
[6], while focal intrahepatic small bile duct obliteration 
and granulomas are typical of PBC [12] together with 
portal inﬂ   ammation, subsequent periportal hepatitis, 
ﬁ   brous septa, bridging necrosis and, ultimately, frank 
cirrhosis. PSC can aﬀ  ect bile ducts of any size and is thus 
characterized by damage, atrophy, and loss of medium 
and large-size bile ducts within or outside the liver, 
leading to concentric periductal ﬁ  brosis and obliteration 
of bile ducts [8]; in the case of small-duct PSC, only liver 
histology can provide evidence in the diagnostic process.
Liver histology is not peculiar in systemic rheumatic 
diseases with hepatic involvement, and diﬀ  erent patterns 
can be observed in patients with liver enzyme 
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© 2011 BioMed Central Ltdabnor  malities undergoing liver biopsy or in autoptical 
studies. Th  e common histological features are summar-
ized in Table 1. Chronic active hepatitis, chronic persis-
tent hepa  titis, cirrhosis, nodular regenerative hyperplasia, 
ﬁ  brosis, steatosis, and granulomas are the major ﬁ  ndings 
reported in rheumatic diseases, along with less speciﬁ  c 
ﬁ  ndings such as mild chronic inﬂ  ammatory cell inﬁ  ltrate 
of the portal space [13,14]. Vascular involvement is not 
uncommon and has been described as intrahepatic small 
vessel arteritis, Budd–Chiari syndrome, or isolated portal 
hypertension. Drug-induced liver injury is signiﬁ  cantly 
more frequent than primary disease-related liver 
involvement and concurrent viral hepatitis or opportu-
nistic infections have to be ruled out in rheumatic 
patients. Finally, amyloidosis is a rare cause of liver 
involvement in chronic systemic rheumatic diseases [15].
The liver and connective tissue disease
Liver involvement in connective tissue diseases is not 
uncommon, but the liver is not the major organ target. In 
systemic lupus erythematosus (SLE), systemic sclerosis 
(SSc), and primary Sjögren’s syndrome (pSS), serologic 
liver dysfunction and histological lesions have been 
described in numerous descriptive studies mostly based 
on case series.
Abnormal liver function tests are common in patients 
with SLE – being reported in 3 to 29% of the patients 
[14], often during disease exacerbations [16]. Numerous 
histopathological patterns can be found in liver biopsies 
of SLE patients, including small artery vasculitis reported 
in up to 21% of the patients [17], nonalcoholic fatty liver 
diseases in 20 to 73%, nodular regenerative hyperplasia in 
5.7%, chronic persistent or active hepatitis in 2.4%, and 
cirrhosis in 1.1% or ﬁ  brosis in 0.8% [17,18]. Moreover, 
anecdotal cases of giant cell hepatitis, granulomatous 
hepatitis, massive hepatic necrosis, cholangitis, isolated 
portal hyper  ten  sion, Budd–Chiari syndrome, and liver 
infarc  tion have also been described. End-stage liver 
disease is a very infrequent ﬁ  nding [14], while cases of 
Budd–Chiari syn  drome have been reported in asso  cia-
tion with anti  phos  pholipid syndrome. Moreover, anti-
phospholipid anti  bodies have been shown to be involved 
in small artery intrahepatic damage and in the patho-
genesis of nodular regenerative hyperplasia.
Gastrointestinal involvement occurs invariably in SSc. 
In a large cohort of patients, some minor degree of liver 
involvement has been reported in 1.1% of the cases – 
while at autopsy liver ﬁ   brosis was found in 8.8% of 
patients, slightly more prevalent compared with non-SSc 
controls [19]. Th  e association between SSc and PBC is 
more signiﬁ  cant and a common pathogenetic trait has 
been suggested [20].
Finally, liver involvement is considered the most 
common non-exocrine feature in pSS [14,21], presenting 
as abnormal liver function tests in 27 to 49% of the patients 
[22]. In two-thirds of the cases cholestasis is found at liver 
biochemistry, and in up to 50% of cases AIH or PBC is 
associated with pSS. When presenting as a primary 
disease-related internal organ involvement, liver disease in 
pSS is associated with inﬂ  ammation markers similar to 
other systemic manifestations of the diseases [23].
The liver and vasculitis
Vasculitis can aﬀ  ect every organ of the digestive system 
but the liver is not commonly involved. Liver involvement 
is limited to polymyalgia/Horton’s arteritis, polyarteritis 
nodosa, Wegener’s granulomatosis, and Behçet’s disease 
[24]. Abnormal liver function tests commonly manifest a 
cholestatic pattern with elevated alkaline phosphatase 
and γ-glutamyl transferase levels that characterize up to 
Table 1. Histopathology of liver involvement in systemic rheumatic diseases
Histological defi  nition  Features
Chronic active hepatitis   Piecemeal necrosis with mononuclear cell infi  ltrate
Chronic persistent hepatitis  Chronic infl  ammatory infi  ltration of the portal tract with preserved lobular architecture and without portal fi  brosis
Cirrhosis Diff  use liver degeneration characterized by fi  brous tissue and regenerative nodules
Fibrosis  Abnormal production of fi  brous tissue in response to liver injury 
Steatosis  Abnormal retention of lipids within hepatocytes
Cholangitis  Infl  ammation of bile ducts
Reactive hepatitis  Aspecifi  c and mild infl  ammatory cell infi  ltrate of portal spaces
Nodular regenerative hyperplasia  Diff  use nodularity of the liver without fi  brosis
Granulomas  Aggregate of epithelioid cells surrounded by lymphocytes
Idiopathic portal hypertension  Increased blood pressure in the veins of the portal system not due to liver diseases
Arteritis  Vessel wall infl  ammation
Giant cell hepatitis  Presence throughout the liver of enlarged multinucleated hepatocytes with abundant cytoplasm
Massive hepatic necrosis  Diff  use hepatocyte necrosis
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Polymyalgic patients with elevated liver enzymes have an 
increased risk to develop Horton’s arteritis [26].
Liver involvement occurs in a variable proportion (16 
to 56%) of patients aﬀ   ected by polyarteritis nodosa, 
although clinical manifestations related to liver disease 
are quite rare; conversely, necrotizing arteritis of the liver 
has been found in the vast majority of patients with 
polyarteritis [27]. Liver injury is rare in Wegener’s 
granulomatosis. Both granulomatous necrotizing hepatic 
involvement and mild nonspeciﬁ  c lobular hepatitis have 
been described. Liver involvement is rarely observed in 
patients with Behçet’s disease, with a predominance of 
Budd–Chiari syndrome.
The liver and arthritis
Among patients with arthritis, hepatic involvement has 
been reported only in cases of rheumatoid arthritis (RA) 
and its variants. Nevertheless, liver injury is not generally 
recognized as a signiﬁ  cant extra-articular feature of RA. 
Abnormal liver tests varying with disease activity, mainly 
elevated alkaline phosphatase, have been reported in 18 
to 50% of patients with RA. Similarly, 65% of unselected 
patients with RA had abnormal liver biopsies – one-half 
having mild portal chronic inﬂ  ammatory inﬁ  ltrate of the 
portal tract and small foci of necrosis, and one in four 
having fatty liver [28]. As in SLE, drug-induced liver 
injury is frequent in RA, especially during nonsteroidal 
anti-inﬂ   ammatory drug (NSAID) and methotrexate 
treatments. Liver involve  ment has also been reported in 
Felty’s syndrome as liver enlargement (68%) and a rise in 
alkaline phosphatase (25%). Liver histology demonstrates 
diﬀ   use lymphocyte inﬁ   ltrate, periportal ﬁ  brosis  with 
lymphocytic inﬁ  ltration, and portal hypertension. Liver 
enlargement and elevated aminotransferases have also 
been reported in adult-onset Still’s diseases, while liver 
biopsies have demonstrated aspeciﬁ   c mild portal 
inﬁ  ltrate of limited signiﬁ  cance [29]. Cases of acute liver 
failure, however, have also been reported.
The liver and overlap syndromes
Patients with signs and symptoms of two or more 
immunologic diseases are considered as having overlap 
syndromes. Overlap syndromes may include AIH and 
PBC or PSC, as largely reported in the literature 
(illustrated in Table 2); patients with overlap syndromes 
manifest both hepatitis and cholestatic biochemical 
proﬁ  les and histological features suggestive of AIH and 
PBC or PSC. AIH and PBC overlap syndrome has been 
reported in almost 10% of adults with AIH or PBC, 
whereas AIH and PSC overlap syndrome has been found 
in 1.4 to 49% of children, adolescents, and young adults 
with AIH or PSC. Transition from one to another liver 
disease is sometimes possible in a time frame of months 
to years [30]. While cases of anti-mitochondrial 
antibody-negative PBC and AIH overlap syndromes have 
been described, there is no clear evidence for the 
existence of a PBC/PSC overlap syndrome. In addition, 
AIH and PBC overlap syndrome has been described in 
patients with SLE, SSc, and pSS [31].
AIH, PBC, and PSC may develop in patients with sys-
temic rheumatic diseases (Table 2). Th   e accurate preva-
lence of overlap diseases is unknown because of a variety 
of ﬂ  aws encountered in the available prevalence studies. 
Th   e majority of data reported only case reports, while in 
case series the liver histology is derived from autoptical 
investigations or liver biopsies performed on selected 
patients frequently with liver enzyme abnormalities.
While in patients with SLE the prevalence of AIH and 
PBC seems similar among patients with liver abnor  mali-
ties, in SSc patients PBC has been reported in 51.2% of the 
cases with liver dysfunction [32] and in more than 50% of 
patients with a CREST (calcinosis, Raynaud, esophago-
pathy, sclerodactily, teleangectasia) variant [33], and AIH 
is rare – only 11 cases have been reported – while only one 
case of SSc/PSC comorbidity has been described.
A higher frequency of AIH and PBC has been reported 
in pSS patients with liver dysfunction undergoing hepatic 
biopsies: these rates ranged between 6 and 47% and 
between 35 and 57%, respectively [34]. Eleven cases of SS 
and PSC have been published and all of the patients also 
had chronic pancreatitis, while in our series SS was a 
frequent comorbidity condition in PBC cases [35]. A vast 
number of single case reports are available. As an 
example, AIH has been described in polymyositis/
dermatomyositis, RA, Still’s disease, polymyalgia, and 
polyarteritis nodosa [36]. On the other hand, PBC has 
been described in polymyositis/dermatomyositis, RA, 
Still’s disease, polymyalgia, Churg–Strauss’s disease, 
micro  scopic polyangiitis, Behcet’s disease, and Schonlein–
Henoch purpura. Finally, PSC has been exceptionally 
reported in association with rheumatic diseases.
The liver and medical therapies in rheumatology
Th   erapeutic strategies for the treatment of autoimmune 
liver disease are essentially based on corticosteroids and 
Table 2. Prevalence of liver disease overlap syndromes in 
selected rheumatic patients
 AIH  PBC  PSC  References
AIH  –  4.2 to 9%  1.4 to 49.1%  [30]
SLE  2.7 to 20%   2.7 to 15%  1 case  [18,27,31]
pSS  6 to 47%   35 to 57%   11 cases   [31,34,35]
SSc  11 cases  51.2%   1 case   [31-33]
AIH, autoimmune hepatitis; PBC, primary biliary cirrhosis; PSC, primary 
sclerosing cholangitis; pSS, primary Sjögren’s syndrome; SLE, systemic lupus 
erythematosus; SSc, systemic sclerosis.
Selmi et al. Arthritis Research & Therapy 2011, 13:226 
http://arthritis-research.com/content/13/3/226
Page 3 of 6immunosuppressant drugs such as methotrexate and 
azathioprine. Th  e exception is provided by PBC, for 
which ursodeoxycholic acid (UDCA) is the only 
established treatment [37]. Th  e combination of UDCA 
and immunosuppressants, albeit rational, failed to prove 
eﬀ  ective or suﬃ   ciently safe in most cases. Conversely, 
methotrexate has been shown to be virtually void from 
consistent adverse eﬀ   ects in the treatment of real-life 
patients with or without concomitant UDCA [38] while 
being burdened by signiﬁ  cant side eﬀ  ects in randomized 
clinical trials [39]. A simpler scenario is provided by AIH, 
for which corticosteroids represent the cornerstone of 
currently utilized regimens [40]. Th  is treatment should 
be considered for all patients with AIH regardless of the 
disease activity at presentation and should be continued 
until 24 months to achieve normalization of liver tests 
and, ideally, resolution of liver inﬂ  ammatory inﬁ  ltrate at 
histology. In cases of incomplete response or relapse, a 
long-term maintenance regimen with azathioprine is 
justiﬁ  ed. Salvage therapy includes cyclosporine or myco-
phenolate mofetil, although more solid data are awaited 
[40] and new frontier therapeutic approaches may prove 
beneﬁ  cial [41].
Management of overlap syndromes between PBC and 
AIH is empirical and guided by the predominant mani-
fes  tations of the disease. Indeed, patients with AIH and 
PBC with higher serum alkaline phosphatase and trans-
aminases are candidates for treatment with cortico-
steroids and UDCA [42].
Of note, potential beneﬁ  ts have been proposed for anti-
TNFα treatments in autoimmune liver diseases although 
human data are scanty. In a murine model, anti-TNFα 
antibodies proved to be eﬀ  ective in reducing liver inﬂ  am-
mation, necrosis, and ﬁ  brosis. Reports on the impact of 
anti-TNFα therapy in patients with inﬂ  ammatory bowel 
diseases or other rheumatologic diseases and conco-
mitant liver diseases [43] demonstrated potential beneﬁ  ts 
for nonalcoholic steatohepatitis and PSC; however, AIH 
and hepatosplenic T-cell lymphoma have also been 
reported [43].
Several are the implications of concomitant liver 
disease for the therapeutic intervention in rheumatologic 
diseases; in fact, the liver is frequently involved in the 
adverse events of systemic treatments utilized in rheuma-
tology. A complete discussion goes beyond the aims of 
the present review article, but it is easy to foresee that 
hepatitis virus reactivation and drug-related liver injuries 
are rapidly becoming a major cause for liver involvement 
in rheumatology with the use of more potent immuno-
suppressants such as biologics [44,45] or hematopoietic 
stem cell transplantation [46]. Detailed recommendations 
on the use of immunomodulatory molecules in patients 
with chronic liver disease were reported by the American 
College of Rheumatology in 2008 for RA [47] while the 
American Association for the Study of Liver Diseases 
also presented practice guidelines in 2009 for the 
manage  ment of patients with hepatitis B virus (HBV) or 
hepatitis C virus (HCV) chronic infection needing 
immuno  suppres  sive therapy [48,49], and clinical 
guidelines are available for viral hepatitis and inﬂ  am-
matory bowel disease treat  ment [50]. Th  ese guidelines 
support the view that the alanine aminotransferase (ALT) 
level, anti-HBsAg, anti-HBsAb, anti-HBcAb IgG and, in 
selected cases, HBV DNA, along with anti-HCV 
antibodies and HCV RNA, should be tested before an 
immunosuppressant treatment is initiated [47,50,51]. 
Currently, a preventive antiviral treatment is recom-
mended in patients with an active chronic HBV infection 
(HBsAg-positive, elevated ALT and serum HBV DNA 
levels >2,000 IU/ml) and in patients with chronic HCV 
infections without extrahepatic contraindications [47,50].
Prophylactic treatment is recommended in patients 
needing nonbiologic or biologic disease-modifying anti-
rheumatic drugs with inactive HBV (HBsAg-positive, 
normal ALT and HBV DNA <2,000 IU/ml; or HBsAg-
negative and anti-HBcAb-positive with or with  out 
HBsAb, normal ALT and HBV DNA <50 IU/ml), and to 
be considered in resolved HBV infection (HBsAg-
negative, HBsAb-positive and/or anti-HBcAb-positive, 
normal ALT and HBV DNA <50 IU/ml) together with 
monitoring of ALT levels and serum HBV DNA in cases 
of long-term lamivudine use [47,50]. Disease-modifying 
antirheumatic drugs such as methotrexate and leﬂ  uno-
mide are contraindicated in cirrhosis secondary to 
chronic HBV and HCV infections, whether treated or 
untreated, for all Child–Pugh stages [47], while biologics 
are contraindicated in both chronic HBV and HCV, 
whether treated or untreated, for those with signiﬁ  cant 
liver injury, deﬁ  ned as chronic Child–Pugh classes B or C 
[47]. Immunosuppressant regimens including gluco  corti-
coids appear to have the highest risk of HBV reactivation 
and HCV replication, so steroid-sparing treatment 
should be adopted when possible although low doses 
appear to be safe [48]. Finally, the use of NSAIDs should 
be carefully evaluated in patients with liver cirrhosis 
regardless of the etiology based on the risk of renal injury 
secondary to tubular ischemia. Referral clinical immu-
nology textbooks report the risk of liver injury related to 
the use of classical anti-inﬂ  ammatory treatments such as 
acetaminophen, NSAIDs, or methotrexate despite the 
rarity of such events in clinical trials [52].
Th  e American College of Rheumatology guidelines 
indicate that when the levels of ALT are greater than 
twofold the upper normal limit, the initiation of disease-
modifying antirheumatic drugs such as metho  trexate, 
leﬂ  unomide, and sulfasalazine is contraindicated, while 
recommendations on when to discontinue the drug are 
not provided [47]. Further, recent prospective data put 
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the risk of liver injury following acetaminophen intake is 
now well deﬁ   ned and recognizes a dose-dependent 
increase, with doses as high as 4 g/day proven to be safe 
in patients with chronic viral hepatitis or recent alcohol 
abuse as well as in patients with compensated liver 
cirrhosis [53]. Conversely, the appearance of NSAID-
induced liver injury appears to be dose independent 
while the new scenarios of biologic-induced autoimmune 
hepatitis [54] will warrant further studies on the long-
term outcomes. A most recent study on the impact of 
methotrexate on liver function tests demon  strated a 
reasonably safe proﬁ   le for this medication if properly 
used [55], thus suggesting that dedicated studies are 
necessary to detect the detrimental potential of immuno-
modulatory treatments. Th  e issue of drug-induced liver 
injury became important with the discovery of the 
possible implications of occult hepatitis B infection [56] 
and the subsequent impact on the widespread use of 
monoclonal antibodies [57] in carriers and cases of 
chronic infections [58]. Finally, we should expect that the 
use of hematopoietic stem cell transplantation will also 
impact liver biology [59,60].
The liver in the present and future of rheumatology
Among patients with systemic rheumatic diseases, those 
with connective tissue diseases may present a mild liver 
involvement mainly related to the underlying disease 
activity that is, subsequently, transient. Progressive liver 
involvement is generally related to the coexistence of 
viral hepatitis or autoimmune liver diseases with 
obviously opposite results of the proposed systemic 
immunosuppressive treatments. Overlap diseases should 
be considered once hepatitic and/or cholestatic bio-
chemical proﬁ  les, either simultaneously or consecutively, 
are not clearly explained by liver involvement of a 
rheumatic disease or by coincidental infection or drug 
toxicity. Finally, we encourage perspective studies to 
determine the impact in clinical practice of old and new 
treatments on the liver biology to overcome ancient 
beliefs [61] and pave the way for the new exciting 
developments in the ﬁ  eld of biologics [62].
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